CA209-9DX: Phase III, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (HCC) at high risk of recurrence after curative resection or ablation.
暂无分享，去创建一个
E. Assenat | S. Paik | M. Shimada | T. Decaens | A. Baron | J. Yoon | A. Heurgue-berlot | L. Balart | N. Takemura | V. Poulart | M. Akce | A. Sehbai | J. Alvarez | M. J. Jimenez Exposito | A. Martín | A. O. Martin